Prostate Cancer and Prostatic Diseases

Papers
(The H4-Index of Prostate Cancer and Prostatic Diseases is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
When precision meets prostate cancer: the rising role of HIFU focal therapy140
Gender-affirming hormone therapy in transgender women and risk of prostate cancer: pathophysiological mechanisms and clinical implications117
Extended LUTS medication use following BPH surgical treatment: a US healthcare claims analysis86
Sexual outcomes in men who have sex with men who underwent radical prostatectomy65
Evaluation of blood and urine based biomarkers for detection of clinically-significant prostate cancer63
Variation in communication of side effects in prostate cancer treatment consultations62
Diagnostic accuracy of magnetic resonance imaging targeted biopsy techniques compared to transrectal ultrasound guided biopsy of the prostate: a systematic review and meta-analysis54
Radical prostatectomy without prostate biopsy based on a noninvasive diagnostic strategy: a prospective single-center study54
Goodbye and thanks for the memories40
Can there be consensus on whether vasectomy is a prostate cancer risk factor?39
Prostate cancer genetic propensity risk score may modify the association between this tumour and type 2 diabetes mellitus (MCC-Spain study)38
Impact of Decipher Biopsy testing on clinical outcomes in localized prostate cancer in a prospective statewide collaborative38
Statins and prostate cancer—hype or hope? The epidemiological perspective37
A Visual Standardized (ViSta) map integrating imaging (MRI), biopsy findings and Specimen Prostate Cancer location37
Dietary interventions to improve body composition in men treated with androgen deprivation therapy for prostate cancer: a solution for the growing problem?36
Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or andro32
Germline alterations among Hispanic men with prostate cancer31
Association between adherence to radiation therapy quality metrics and patient reported outcomes in prostate cancer31
An updated model for predicting side-specific extraprostatic extension in the era of MRI-targeted biopsy30
Concerns regarding prostate cancer screening guidelines in minority populations30
Follow-up on patients with initial negative mpMRI target and systematic biopsy for PI-RADS ≥ 3 lesions – an EAU-YAU study enhancing prostate cancer detection30
Social determinants of health and surgical outcomes of minimally invasive radical prostatectomy: a national population-based study28
Correction: Protective effect of pharmacological castration on metabolic perturbations and cardiovascular disease in the hyperglycemic male ApoE−/−:Ins2+/Akita mouse model27
Impact of medical treatment on storage and voiding LUTS, nocturia, and quality of life in men at risk for progression26
A randomized controlled trial evaluating low-intensity shockwave therapy for treatment of persistent storage symptoms following transurethral surgery for benign prostatic obstruction26
Comparison of procedural anxiety and pain associated with conventional transrectal ultrasound prostate biopsy to magnetic resonance imaging-ultrasound fusion-guided biopsy: a prospective cohort trial26
Neurovascular structure-adjacent frozen-section examination (NeuroSAFE) during robot-assisted radical prostatectomy: a systematic review and meta-analysis of comparative studies26
Impact of peritoneal reconfiguration on lymphocele formation after robot-assisted radical prostatectomy with pelvic lymph node dissection: a systematic review and meta-analysis of randomized controlle26
Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer26
0.06183910369873